Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Overall Survival in Patients with Myelofibrosis Who Have Discontinued Ruxolitinib: A Literature Review

Derek Tang, PhD BSPharm, Ankush Taneja, Preety Rajora, Indeg Sly, Niall James Davison

Blood (2019) 134 (Supplement_1): 3457.

https://doi.org/10.1182/blood-2019-122904

Published: 2019

Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD

Blood (2019) 134 (Supplement_1): 2963.

https://doi.org/10.1182/blood-2019-126189

Published: 2019

Journal Articles

Imetelstat Sensitizes Hematopoietic Malignancy Cells to Genotoxic Agent Via Suppression of Telomerase Mediated DNA Repair Process

Daisuke Hidaka, Masahiro Onozawa, Naohiro Miyashita, Masao Nakagawa, Daigo Hashimoto, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 3369.

https://doi.org/10.1182/blood-2019-122999

Published: 2019

Journal Articles

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2019) 134 (Supplement_1): 4248.

https://doi.org/10.1182/blood-2019-127435

Published: 2019

Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study

Raajit K. Rampal, MD PhD, Srdan Verstovsek, MD PhD, Sean M Devlin, PhD, Eytan M. Stein, MD, Tapan M. Kadia, MD, Michael J. Mauro, MD, Naveen Pemmaraju, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Kelly Marek, Prithviraj Bose, MD

Blood (2018) 132 (Supplement 1): 354.

https://doi.org/10.1182/blood-2018-99-114125

Published: 2018

Journal Articles

Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients

Blood (2018) 132 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2018-99-116289

Published: 2018

Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux

Blood (2018) 132 (Supplement 1): 463.

https://doi.org/10.1182/blood-2018-99-114877

Published: 2018

Journal Articles

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Ali Younas Khan, MD, Nimra Iftikhar, MD, Awais Ijaz, MD, Muhammad Junaid Tariq, MD, Faiza Jamil, MD, Arshia Akbar, MD, Anum Qureshi, Jemin Aby Jose, MD, Ahmad Kamal, MD, Muhammad Abu Zar, MD, Madeeha Shafqat, Insija Ilyas Selene, MBBS, Shehroz Aslam, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2018-99-115867

Published: 2018

Journal Articles

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, MD, Bruno Martino, MD, Dietger Niederwieser, MD, Andreas Reiter, MD, Bart L Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Jacqueline Bussolari, PhD, Eugene Zhu, PhD, Fei Huang, PhD, Esther Rose, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye M. Feller, MD, Jean-Jacques Kiladjian, MD PhD

Blood (2018) 132 (Supplement 1): 685.

https://doi.org/10.1182/blood-2018-99-115163

Published: 2018

Journal Articles

Telomerase Inhibition Impairs Self-Renewal of ß-Catenin Activated Myeloproliferative Neoplasm Progenitors

Wenxue Ma, MD PhD, Cayla Mason, BS, Ping Chen, MD PhD, Qingfei Jiang, PhD, Nathan Delos Santos, BS, Elisa Lazzari, PhD, Sheldon Morris, MD MPH, Phoebe Mondala, BS, Jane Isquith, BS, MS, Fei Huang, PhD, Larissa Balaian, PhD, Catriona Jamieson, MD PhD

Blood (2017) 130 (Supplement 1): 2860.

https://doi.org/10.1182/blood.V130.Suppl_1.2860.2860

Published: 2017

Journal Articles

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Jiajing Qiu, Fei Huang, PhD, Ronald Hoffman, MD, Xiaoli Wang, PhD

Blood (2017) 130 (Supplement 1): 1654.

https://doi.org/10.1182/blood.V130.Suppl_1.1654.1654

Published: 2017

Journal Articles

Integrated Molecular Analysis Identifies Replicative Stress As Sensitizer to Imetelstat Therapy in AML

Claudia Bruedigam, Amy H Porter, Brad Wackrow, Jasmin Straube, PhD, Leanne T Cooper, Axia Song, Stanley Chun-Wei Lee, PhD, Omar Abdel-Wahab, MD, Geoffrey R Hill, MD, Steven W. Lane, MD PhD

Blood (2017) 130 (Supplement 1): 798.

https://doi.org/10.1182/blood.V130.Suppl_1.798.798

Published: 2017

Journal Articles

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Pierre Fenaux, MD PhD, Azra Raza, MD, Edo Vellenga, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Irina Samarina, MD, Koen Van Eygen, MD, Maria Díez-Campelo, MD PhD, Mrinal M. Patnaik, MDMBBS, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Aleksandra Rizo, MD PhD, David P. Steensma, MD

Blood (2017) 130 (Supplement 1): 4256.

https://doi.org/10.1182/blood.V130.Suppl_1.4256.4256

Published: 2017

Journal Articles

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Raajit K. Rampal, MD, PhD, Roni Tamari, MD, Nan Zhang, MS, Caroline Jane McNamara, MBBS, Franck Rapaport, PhD, Rivka Litvin, Molly A. Maloy, MS, Hugo Castro-Malaspina, MD, Sergio Giralt, MD, Rona Singer Weinberg, PhD, John Mascarenhas, MD, Ruben A. Mesa, MD, Damiano Rondelli, MD, Amylou C. Dueck, PhD, Ross L. Levine, MD, Vikas Gupta, MD FRCP, FRCPath, Ronald Hoffman, MD

Blood (2016) 128 (22): 2301.

https://doi.org/10.1182/blood.V128.22.2301.2301

Published: 2016

Journal Articles

The Preclinical Efficacy of a Novel Telomerase Inhibitor, Imetelstat, in AML - a Randomized Trial in Patient-Derived Xenografts

Claudia Bruedigam, PhD, Brad Wackrow, Axia Song, Amy H Porter, Stanley Chun-Wei Lee, PhD, Andrew S. Moore, MBBS FRACP PhD, Omar Abdel-Wahab, MD, Steven W Lane, PhD

Blood (2016) 128 (22): 578.

https://doi.org/10.1182/blood.V128.22.578.578

Published: 2016

Journal Articles

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Monika Haubitz, PhD, Elisabeth Oppliger Leibundgut, PharmD, Ingrid Helsen, Dania Hiltbrunner, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Röth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2016) 128 (22): 1938.

https://doi.org/10.1182/blood.V128.22.1938.1938

Published: 2016

Journal Articles

Telomerase Inhibition with Imetelstat Eradicates β-Catenin Activated Blast Crisis Chronic Myeloid Leukemia Stem Cells

Wenxue Ma, MD, PhD, Cayla N Mason, BS, Ping Chen, MD PhD, Nathaniel Delos Santos, BS, Jiang Qingfei, PhD, Elisa Lazzari, PhD, Fei Huang, Larisa Balaian, PhD, Catriona H.M. Jamieson, MD PhD

Blood (2016) 128 (22): 3065.

https://doi.org/10.1182/blood.V128.22.3065.3065

Published: 2016

Journal Articles

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Elisabeth Oppliger Leibundgut, PharmD, Monika Haubitz, PhD, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Roeth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2015) 126 (23): 57.

https://doi.org/10.1182/blood.V126.23.57.57

Published: 2015

Journal Articles

Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis

Ayalew Tefferi, MD, Aref Al-Kali, MD, Kebede H. Begna, MD, Mrinal M Patnaik, MBBS, Terra L. Lasho, PhD, Xiaolin Wang, ScD, Ying Wan, PhD, Curtis A. Hanson, MD

Blood (2015) 126 (23): 55.

https://doi.org/10.1182/blood.V126.23.55.55

Published: 2015

Journal Articles

Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status

Caroline R Cantilena, BA, Xin Zhao, MD PhD, Sachiko Kajigaya, PhD, Neil Dunavin, MD, Xin Tian, PhD, Stephen A. Strickland, MD, Bipin N. Savani, MD, Sanjay R. Mohan, MD, Katayoun Rezvani, MDPhD, Xingmin Feng, PhD, Danielle M. Townsley, MD, Minoo Battiwalla, MDMS, Sawa Ito, MD, Austin John Barrett, MDFRCP,FRCPath

Blood (2015) 126 (23): 1267.

https://doi.org/10.1182/blood.V126.23.1267.1267

Published: 2015

NARROW

Overall Survival in Patients with Myelofibrosis Who Have Discontinued Ruxolitinib: A Literature Review

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Imetelstat Sensitizes Hematopoietic Malignancy Cells to Genotoxic Agent Via Suppression of Telomerase Mediated DNA Repair Process

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study

Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

Telomerase Inhibition Impairs Self-Renewal of ß-Catenin Activated Myeloproliferative Neoplasm Progenitors

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Integrated Molecular Analysis Identifies Replicative Stress As Sensitizer to Imetelstat Therapy in AML

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

The Preclinical Efficacy of a Novel Telomerase Inhibitor, Imetelstat, in AML - a Randomized Trial in Patient-Derived Xenografts

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Telomerase Inhibition with Imetelstat Eradicates β-Catenin Activated Blast Crisis Chronic Myeloid Leukemia Stem Cells

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis

Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only